ArticleJournal of clinical hypertension (Greenwich, Conn.)2025
Cost-Effectiveness of Radiofrequency Renal Denervation in Taiwan Based on Clinical Evidence and Regional Event Rates.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Renal Denervation in Cardiovascular Diseases: Mechanisms, Evidence, and Expanding Applications.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiofrequency renal denervation (RF RDN) is recognized as an adjunct therapy for hypertension. This study evaluated the cost-effectiveness of RF RDN for the Taiwanese healthcare system using results from the SPYRAL HTN-ON MED randomized, sham-controlled trial. A decision-analytic Markov model projected clinical events, costs, and quality-adjusted life-years (QALYs) for RF RDN versus standard-of-care (SoC) in an Asian population context. Clinical event risk reductions from treatment effects on office-based systolic blood pressure (oSBP) were derived from a meta-regression study of 47 hypertension trials. SPYRAL HTN-ON MED demographics and results (oSBP reduction of 4.9 mmHg against sham) were used in the base case analysis. The incremental cost-effectiveness ratio (ICER) was assessed against a willingness-to-pay (WTP) threshold of three million Taiwan dollars (TWD) per QALY gained. Compared to SoC, RF RDN was projected to reduce clinical events, with relative risks of 0.80, 0.88, and 0.74 for stroke, myocardial infarction (MI), and heart failure (HF), respectively. The incremental costs and QALYs were 216 381 TWD and 0.25, respectively, resulting in an ICER of 850 932 TWD per QALY gained. The ICER was cost-effective across a broad range of uncertainty analyses. Model-based projections adjusted for East Asian event rates suggest RF RDN may significantly reduce events, making it a cost-effective intervention in the Taiwanese healthcare system for treating uncontrolled hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.